TW202346288A - 用於抑制ｋｉｆ１８ａ之化合物 - Google Patents

用於抑制ｋｉｆ１８ａ之化合物 Download PDF

Info

Publication number
TW202346288A
TW202346288A TW112115805A TW112115805A TW202346288A TW 202346288 A TW202346288 A TW 202346288A TW 112115805 A TW112115805 A TW 112115805A TW 112115805 A TW112115805 A TW 112115805A TW 202346288 A TW202346288 A TW 202346288A
Authority
TW
Taiwan
Prior art keywords
group
compound
alkyl
cycloalkyl
pharmaceutically acceptable
Prior art date
Application number
TW112115805A
Other languages
English (en)
Chinese (zh)
Inventor
德里克 Ａ 柯根
Original Assignee
美商佛拉斯托醫療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商佛拉斯托醫療公司 filed Critical 美商佛拉斯托醫療公司
Publication of TW202346288A publication Critical patent/TW202346288A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW112115805A 2022-04-28 2023-04-27 用於抑制ｋｉｆ１８ａ之化合物 TW202346288A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202263336183P 2022-04-28 2022-04-28
US63/336,183 2022-04-28
US202263389237P 2022-07-14 2022-07-14
US63/389,237 2022-07-14
US202363456342P 2023-03-31 2023-03-31
US63/456,342 2023-03-31

Publications (1)

Publication Number Publication Date
TW202346288A true TW202346288A (zh) 2023-12-01

Family

ID=86604316

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112115805A TW202346288A (zh) 2022-04-28 2023-04-27 用於抑制ｋｉｆ１８ａ之化合物

Country Status (11)

Country Link
US (1) US20230382889A1 (enExample)
EP (1) EP4514790A1 (enExample)
JP (1) JP2025515484A (enExample)
KR (1) KR20250021398A (enExample)
CN (1) CN119451951A (enExample)
AU (1) AU2023261964A1 (enExample)
CA (1) CA3256989A1 (enExample)
IL (1) IL316450A (enExample)
MX (1) MX2024013215A (enExample)
TW (1) TW202346288A (enExample)
WO (1) WO2023212240A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20211475A1 (es) 2018-12-20 2021-08-05 Amgen Inc Inhibidores de kif18a
WO2023028564A1 (en) 2021-08-26 2023-03-02 Volastra Therapeutics, Inc. Spiro indoline inhibitors of kif18a
AU2023254325A1 (en) * 2022-04-15 2024-10-17 Wuhan Humanwell Innovative Drug Research and Development Center Limited Company Kif18a inhibitor and use thereof
WO2024039829A1 (en) 2022-08-18 2024-02-22 Accent Therapeutics, Inc. Inhibitors of kif18a and uses thereof
WO2025020624A1 (zh) * 2023-07-25 2025-01-30 捷思英达控股有限公司 一种苯环衍生物、其制备方法及其在医药上的应用
WO2025036479A1 (zh) * 2023-08-16 2025-02-20 上海湃隆生物科技有限公司 驱动蛋白kif18a抑制剂及其应用
WO2025090640A1 (en) 2023-10-23 2025-05-01 Volastra Therapeutics, Inc. Solid formulations and polymorphic forms of indoline inhibitors of kif18a
WO2025247067A1 (zh) * 2024-05-29 2025-12-04 上海复星医药产业发展有限公司 Kif18A抑制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
CN1087725C (zh) 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
CA3123227A1 (en) * 2018-12-20 2020-06-25 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
MX2021007157A (es) * 2018-12-20 2021-08-16 Amgen Inc Heteroarilamidas utiles como inhibidores de kif18a.
US12540129B2 (en) * 2019-08-02 2026-02-03 Amgen Inc. KIF18A inhibitors
CN114302880B (zh) * 2019-08-02 2025-07-15 美国安进公司 Kif18a抑制剂
CA3224249A1 (en) * 2021-06-25 2022-12-29 Hangzhou Innogate Pharma Co., Ltd. Compound as kif18a inhibitor

Also Published As

Publication number Publication date
EP4514790A1 (en) 2025-03-05
IL316450A (en) 2024-12-01
WO2023212240A1 (en) 2023-11-02
MX2024013215A (es) 2024-12-06
CA3256989A1 (en) 2023-11-02
US20230382889A1 (en) 2023-11-30
AU2023261964A1 (en) 2024-11-07
KR20250021398A (ko) 2025-02-12
CN119451951A (zh) 2025-02-14
JP2025515484A (ja) 2025-05-15

Similar Documents

Publication Publication Date Title
US20230382889A1 (en) Compounds for inhibiting kif18a
JP7579789B2 (ja) 免疫調節剤、組成物およびその使用方法
JP7112324B2 (ja) Ｒｓｖ阻害剤としてのベンゾジアゼピン誘導体
KR102759231B1 (ko) 키나제 억제제로서의 아미노피롤로트리아진
CA3165148A1 (en) Pyrazolyl derivatives useful as anti-cancer agents
JP2021520350A (ja) Ｂｒｍ標的化化合物および関連使用方法
AU2017237930B2 (en) Allosteric modulators of nicotinic acetylcholine receptors
US12084420B2 (en) Indoline compounds for inhibiting KIF18A
JP2017512794A (ja) ＴｒｋＡキナーゼ阻害薬、その組成物および方法
JP2017512786A (ja) ＴｒｋＡキナーゼ阻害薬、その組成物および方法
IL285246B2 (en) Substituted bicyclic compounds as farnesoid x receptor modulators
US20170015654A1 (en) Pyridazine compound
KR20200083528A (ko) 파르네소이드 x 수용체 조정제로서의 스피로시클릭 화합물
US20240174683A1 (en) Map4k1 inhibitors
SG11202108796YA (en) Substituted bicyclic compounds as farnesoid x receptor modulators
TW202440092A (zh) Akt1之共價修飾劑及其用途
TW202229273A (zh) 稠合雜芳基化合物及其作為CaMKII抑制劑之用途
WO2025015269A1 (en) Compounds, compositions, and methods
CN116635028A (zh) c-MYC mRNA翻译调节剂及其在治疗癌症中的用途
WO2025171340A1 (en) The treatment of calcitonin- and/or amylin-receptor associated conditions
EP4463452B1 (en) C-myc mrna translation modulators and uses thereof in the treatment of cancer
WO2025170939A1 (en) Proteasome inhibitors for the treatment of malaria
AU2023305002A1 (en) C-myc mrna translation modulators and uses thereof in the treatment of cancer
US20260069602A1 (en) Compounds, compositions, and methods
US20260042760A1 (en) Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity